InMed FY26 net loss widens to US$12.9 million; discontinued-ops sales drop 36% to US$3.2 million
INM•BayMedica discontinued operations sales decline
BayMedica discontinued operations recorded sales of USD 3.2 million, down from USD 5 million.
FY26 results show wider loss and higher expenses
InMed Pharmaceuticals posted a net loss attributable to common shareholders of USD 12.99 million, widening from USD 8.16 million.
Operating expenses climbed to USD 11.61 million from USD 8.47 million, including R&D of USD 3.03 million and G&A of USD 6.66 million.
Cash, cash equivalents and short-term investments fell to USD 2.23 million from USD 10.79 million.
Merger with Mentari remains targeted for Q4 2026
The merger with Mentari remains targeted for Q4 2026, with expected aggregate pre-closing financing of about USD 490 million and a planned CVR for legacy assets.
